- Some members of Abu Dhabi’s ruling household taking part in Sinopharm vaccine trial
- Sinopharm COVID-19 vaccine trial will monitor immune response of 900 youngsters.
- The UAE, which has among the many world’s highest immunisation charges, on Wednesday registered 2,011 new coronavirus infections Thursday.
DUBAI: Some members of Abu Dhabi’s ruling household are taking part in a trial administering China’s Sinopharm COVID-19 vaccine to youngsters aged 3-17, the emirate’s media workplace stated.
The trial will monitor the immune response of 900 youngsters “in preparation to vaccinate children in the near future”, Abu Dhabi Media Workplace stated in a Twitter submit on Wednesday.
Sheikh Theyab bin Mohammed, a son of the United Arab Emirate’s de facto ruler and Abu Dhabi’s crown prince Sheikh Mohammed bin Zayed Al Nahyan, accompanied his youngsters, nieces and nephews to take part within the immune bridge research, it stated.
Learn extra: Sinopharm says it has capability to supply over 1 billion COVID-19 vaccine doses in 2021
The UAE in Could accredited the Pfizer-BioNTech vaccine for emergency use in youngsters aged 12-15. Dubai, the second-largest member of the UAE federation, began inoculating that age group this month.
The UAE, which has among the many world’s highest immunisation charges, on Wednesday registered 2,011 new coronavirus infections to take its complete to 603,961 circumstances with 1,738 deaths. It doesn’t present a breakdown for every of its seven emirates.
The Gulf state led Part III scientific trials of the vaccine produced by China’s state-owned drugmaker Sinopharm and has began manufacturing it underneath a three way partnership between Sinopharm and Abu Dhabi-based know-how firm Group 42.